Abstract
Aim:To investigate the potential anti-inflammatory and biochemical effects of Moringa peregrina leaf extracts on testosterone-induced benign prostatic hyperplasia (BPH) in rats. Methods:Six groups of rats (each group included 5 rats) were included in this study. The groups included: 1) the control group, 2) the testosterone-induced BPH group, 3) with 50 mg/kg bwt (bodyweight) oil-treated BPH, 4) with 100 mg/kg bwt. oil-treated BPH, 5) with 500mg/kg bwt. ethanol treated BPH and 6) with 1,000 mg/kg bwt. aqueous treated BPH group. Biochemical markers were measured to evaluate the effect of M. peregrina leaf extracts.Results:Our results showed a significant improvement in the thickness of epithelial cells of the BPH glandular tissues when treated with different M. peregrina extracts (p < 0.05). In addition, M. peregrina extracts showed anti-inflammatory, anti-proliferative and anti-angiogenesis effects on the BPH tissues by reduction of IL-6, PCNA and VEGF-A, respectively. Conclusion:Our preclinical study concluded that M. peregrina leaf extracts showed a significant effect on BPH by reducing inflammation, proliferation, and angiogenic processes with no signs of toxicity.
Highlights
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that can affect greater than 25% of males over 50 years old and the majority of males in their 80s (McVary, 2006)
Testosterone-induced BPH rats that were treated with M. peregrina extracts did not show any significant reduction in the PW: BW ratios (Figure 1)
This study investigated the effect of administering leaf extracts of M. peregrina on testosterone-induced BPH in vivo using male Sprague-Dawley rats
Summary
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that can affect greater than 25% of males over 50 years old and the majority of males in their 80s (McVary, 2006). Most of the current active clinical treatments in BPH involve procedural interventions accompanied by conventional treatments of beta-blockers and 5-alpha reductase inhibitors (5-ARIs) depending on the size of the prostate. Likewise, another treatment option includes the use of phosphodiesterase-5 (PDE-5) inhibitors (Clifford and Farmer 2000; Van Asseldonk et al, 2015). A list of different phytotherapy drugs to treat BPH has been drawn up as an alternative to conventional treatments assuming possible lower side effects (Migdady et al, 1998; Zlotta et al, 2005; Keehn et al, 2016; Al-Trad et al, 2017). Sativa on animal models in which they reported a reduction in prostate
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
